Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 09 August 2018
Indication(s)
Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.
Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Chronic Spontaneous Urticaria (CSU)
Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.
+ 7 more
Chronic Spontaneous Urticaria (CSU)
Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.
+ 7 more
Related Content
Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in subjects with metastatic Merkel cell carcinoma (MCC).
Added 1 year ago
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma (BOLT)
This study will assess the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
Added 8 years ago
A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent...
Added 1 year ago
A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
The safety of ixekizumab (LY2439821) and any side effects that might be associated with it....
Added 1 year ago
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Background: No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because the mutation burden of the tumor is high...
Added 7 months ago
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Background: Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease. Current standard care uses various cytotoxic chemotherapy regimens...
Added 1 year ago
Avelumab and other recent advances in Merkel-cell carcinoma.
Merkel-cell carcinoma (MCC) is a rare but aggressive form of skin cancer that occurs in the elderly, is associated with UV radiation and immunosuppression. Initial treatment consists of wide excision with adjuvant radiation.
Added 1 year ago
Management of primary cutaneous squamous cell carcinoma
This guideline provides recommendations for referral, management and follow up of patients aged 18 years and over with primary invasive SCC, including SCC arising: on sun-exposed (SE) and non-SE sites.
Added 4 years ago
British Association of Dermatologists’ guidelines for the management of squamous cell carcinoma in situ (Bowen’s disease) 2014
The overall objective of the guideline is to provide up-to-date, evidence-based recommendations for the management of squamous cell carcinoma (SCC) in situ (Bowen’s disease).
Added 5 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/002204 |
Orphan designation | No |
Date First Approved | 14-12-2011 |
Type | Medicinal product subject to medical prescription |
Marketing authorisation holder | Biofrontera Bioscience GmbH |